Bio-Techne Corp (TECH): Cash & Equivalents
$264.71M
As of 2026-06-30
+13.6%
3-year compound annual growth
+5.9%
5-year compound annual growth
+15.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $264.71M | +63.2% | 2026-08-24, Balance as of period end |
| 2025-06-30 | $162.19M | +6.8% | 2026-08-24, Balance as of period end |
| 2024-06-30 | $151.79M | -15.9% | 2025-08-22, Balance as of period end |
| 2023-06-30 | $180.57M | +4.6% | 2024-08-22, Balance as of period end |
| 2022-06-30 | $172.57M | -13.3% | 2023-08-23, Balance as of period end |
| 2021-06-30 | $199.09M | +35.8% | 2022-08-24, Balance as of period end |
| 2020-06-30 | $146.62M | +45.3% | 2021-08-25, Balance as of period end |
| 2019-06-30 | $100.89M | -17.3% | 2020-08-26, Balance as of period end |
| 2018-06-30 | $121.99M | +33.2% | 2019-11-06, Balance as of period end |
| 2017-06-30 | $91.61M | +42.6% | 2019-11-06, Balance as of period end |
| 2016-06-30 | $64.24M | +17.8% | 2018-08-27, Balance as of period end |
| 2015-06-30 | $54.53M | -82.9% | 2017-09-07, Balance as of period end |
| 2014-06-30 | $318.57M | +94.5% | 2016-08-29, Balance as of period end |
| 2013-06-30 | $163.79M | +40.4% | 2015-08-31, Balance as of period end |
| 2012-06-30 | $116.67M | +50.3% | 2014-08-29, Balance as of period end |
| 2011-06-30 | $77.61M | -17.6% | 2013-08-29, Balance as of period end |
| 2010-06-30 | $94.14M | -41.5% | 2012-08-29, Balance as of period end |
| 2009-06-30 | $160.94M | n/a | 2011-08-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $2.60B | +34.7% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $839.00M | +26.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
Compare TECH, NVAX, HALO, BCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗